APA

Bicakli D. H., Varol U., Degirmenci M., Tunali D., Cakar B., Durusoy R., Karaca B., Sanli U. A. & Uslu R. (20160405). Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315. : Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Chicago

Bicakli Derya Hopanci, Varol Umut, Degirmenci Mustafa, Tunali Didem, Cakar Burcu, Durusoy Raika, Karaca Burcak, Sanli Ulus Ali and Uslu Ruchan. 20160405. Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315. : Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Harvard

Bicakli D. H., Varol U., Degirmenci M., Tunali D., Cakar B., Durusoy R., Karaca B., Sanli U. A. and Uslu R. (20160405). Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315. : Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

MLA

Bicakli Derya Hopanci, Varol Umut, Degirmenci Mustafa, Tunali Didem, Cakar Burcu, Durusoy Raika, Karaca Burcak, Sanli Ulus Ali and Uslu Ruchan. Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315. : Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 20160405.